Filter by Cancer
- Bladder cancer
- Myeloma
- Leukemia
- Breast cancer
- Colon cancer
- Esophageal cancer
- Kidney cancer
- Colorectal cancer
- Liver cancer
- Lung cancer
- Hodgkin's disease
- Lymphoma
- Mesenteric Lymphadenitis
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Rectal cancer
- Skin cancer
- Small Intestine cancer
- Spleen cancer
- Stomach cancer
- Ureteral cancer
- Urethral cancer
- Uterine cancer
- White blood cells
ADC
- 3A4-PL1601ADC Therapeutics
- 9MW2821Mabwell (Shanghai) Bioscience Co., Ltd.
- A166 ADCKlus Pharma, the US subsidiary of China-based Kelun-Biotech.
- AB-3A4 ADCAlethia Biotherapeutics
- ABBV-011Abbvie
- ABBV-176 (ABV176)Abbvie
- ABBV-319Abbvie
- ABBV-3373AbbVie
- ABBV-400Abbvie
- ABBV-706Abbvie
- AbGn-107 | Ab1-18Hr1AbGenomics BV | Taiwan Branch
- AbGn-108AbGenomics International
- AbGn-110AbGenomics International
- Actinium (225Ac) lintuzumab satetraxetan
- ADCT-502ADC Terapeutics
- ADCT-701ADC Therapeutics
- ADCT-901ADC Therapeutics
- ADRX-0706Adcentrx Therapeutics
- AG02A&G Pharmaceuticals
- AGS-16C3F (AGS 16C3F / AGS-16M8F)Agensys/Astellas
- AGS-16M8F (AGS 16C3F / AGS-16C3F)Agensys/Astellas
- AGS62P1Agensys/Astellas
- ALT-P73SBIO | Alteogen
- AMG 224Amgen
- AMG-595Amgen
- AMG172Amgen, Inc
- Anetumab corixetan
- Anetumab Ravtansine | BAY 94-9343Bayer HealthCare Pharmaceuticals in association with ImmunoGen Inc.
- Anti-ADAM9 ADC (Anti-ADAM9-sulfoSPDB-DM4)Macrogenics and ImmunoGen
- Anti-ADAM9 ADC (Anti-ADAM9(C442)-DGN549)Macrogenics and ImmunoGen
- Anti-CD19 ATAC (anti-CD19 ADC)Heidelberg Pharma/Wilex
- Anti-CD22-NMS249Genentech and Nerviano Medical Sciences
- Anti-CD70-ADC (CD70-ADC)Ambrx
- Anti-cMET ADC (CBT-161)Sorrento Therapeutics
- Anti-endosialin-MC-VC-PABC-MMAEGenzyme
- Anti-ETBR (RG-7636)Genentech/Roche
- anti-HER-3 ADCMediaPharma
- anti-TEM-1 Antibody-Drug Conjugate (TEM-1-ADC).MediaPharma S.r.l.
- Anti-TM4SF1 ADCThe Center for Vascular Biology Research and the Departments of Angiex; Pfizer; Pathology, Beth Israel Deaconess Medical Center (BIDMC); Harvard Medical School, Boston, Massachusetts
- Aprutumab ixadotin | BAY 1187982Bayer HealthCare Pharmaceuticals
- AR-001 | YBL-001Y-Biologics
- ARX517-PSMA-ADCAmbrx
- ARX788 HER2 ADC | ARX788Zhejiang Medicine Co. | Ambrx
- ASG-22CEAstellas Pharma Inc/Agensys, Inc. Seattle Genetics, Inc.
- ASN-004 (ASN 004)Asana Biosciences
- ATG-022Antengene Corporation ( Antengene Biologics)
- AVID100Formation Biologics | Forbius
- AVID300 | AVID 300Formation Biologics
- AZD8205AstraZeneca
- Azintuxizumab Vedotin | ABBV-838AbbVie
- Azonafide-ADCOncolinx
- Basiliximab Sarotalocan
- BAT8001Bio-Thera Solutions
- BAT8003Bio-Thera Solutions
- BAT8006Bio-Thera Solutions, Ltd
- BAT8007Bio-Thera Solutions (Guangzhou, China)
- BAY79-4620Bayer HealthCare
- BB-1701 | HER2-Targeting ADCBliss Biopharmaceutical (Hangzhou) Co., Ltd. (Headquarters: Zhejiang Province, China) in collaboration with Eisai & Co, Ltd.
- BB-1705Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- BDC-1001Bolt Biotherapeutics
- Belantamab mafodotin | Blenrep® | GSK2857916 | J6M0-mcMMAFGlaxoSmithKline (GSK) Co-developer: Seattle Genetics
- BIIB-015 | BIIB015Biogen
- Bivatuzumab mertansine | Anti-CD44v6-DM1 | BIWI-1Boehringer Ingelheim | ImmunoGen
- BL-B01D1SystImmune, Inc in collaboration with Sichuan Baili Pharmaceutical Co.
- BL-B029A1Systimmune
- BL-M002A2Systimmune
- BL-M005A2Systimmune
- BMS986148 | BMS-986148Bristol-Myers Squibb (BMS)
- BMS986288 | BMS-986288Bristol Myers Squibb In collaboration with CytomX
- Brentuximab vedotin | SGN35 | Adcetris®Seattle genetics, Inc. (Bothell WA USA) / Takeda Pharmaceutical Co. Ltd. (Osaka Japan)
- BRY812BioRay Pharmaceutical Co
- Bstrongximab-ADCCureMeta
- BT1718 | BT 1718 | BT-1718Bicycle Therapeutics
- BYON3521 ADCByondis
- BYON4413 ADCByondis
- c-MET ADCConcortis Biotherapeutics
- Camidanlumab tesirine | ADCT-301 | HuMax-TAC-ADCGenmab | ADC Therapeutics
- Cantuzumab mertansine | huC242-DM1 | SB-408075GlaxoSmithKline (GSK) / ImmunoGen
- Cantuzumab Ravtansine | IMGN-242ImmunoGen
- CC-99712 - Anti-BCMA ADCBristol-Myers Squibb (Celgene) Sutro Biopharma
- CD184-Dasatinib (CD184-Dasatinib-ADC)Ambrx
- CD184-FK506Ambrx
- CD22-4APCatalent Pharma Solutions and Triphase Accelerator Corporation
- CD70-glucocorticoid ADCMerck & Co and Ambrx
- CDX-014Celldex Therapeutics
- Cetuximab sarotalocan | ASP-1929 | RM-1929Rakuten Medical (Aspyrian Therapeutics)
- Cirmtuzumab Vedotin | UC-961ADC3Thomas Kipps, University of California, San Diego
- Clivatuzumab TetraxetanImmunmedics
- CMB-401 | hCTMO1-calicheamicin | CDP-671Pfizer (Wyeth Pharmaceuticals); Celltech
- CMG901KYM Biosciences (A joint venture of Keymed Biosciences and Lepu Biopharma) AstraZeneca
- Cofetuzumab pelidotin | PF-06647020 | ABBV-647Pfizer Stemcentrx (now AbbVie) In collaboration with Indiana University
- Coltuximab Ravtansine | SAR 3419ImmunoGen (previously also Sanofi)
- CPO301CSPC Pharmaceutical Group
- CRB-701 (SYS6002)Corbus Pharmaceuticals CSPC Megalith Biopharmaceutical, a subsidiary of CSPC Pharmaceutical Group
- CUSP06OnCusp Therapeutics
- CX-2029CytomX and AbbVie
- Cymac-001 (anti-CD163-dexamethasone ADC)Affinicon
- D3-GPC2-PBD (anti-GPC2 ADC)Children's Hospital of Philadelphia (CHOP
- Dafsolimab Setaritox | SPV-T3a-RTAXenikos
- Datopotamab deruxtecan | DS-1062 | TROP2 ADCDaiichi Sankyo
- DB-1303 | BNT323Duality Biologics in collaboration with BionTech
- DB-1311Duality Biologics in collaboration with BionTech
- DEDN6526A (RG-7636 / RG7636)Genentech/Roche
- Denintuzumab mafodotin | SGN-CD19A | SGN-19A | hBU12-491Seattle Genetics
- Depatuxizumab Mafodotin | ABT-414AbbVie (prior sponsor, Abbott)
- Derlotuximab BiotinPeregrine Pharmaceuticals
- DHES0815A | RG6148Genentech/Roche
- Disitamab Vedotin | RC-48 | RC 480-ADC | RC48 | 爱地希® | Aidixi®Remegen Biosciences (Shandong China), Yantai Rongchang Biological Engineering (manufactured by MabPlex)
- DMOT4039A (DMOT-4039A / RG7600 / RG 7600)Genentech Inc. (South San Francisco, CA, USA) / Roche, F. Hoffmann-La Roche Ltd. (Basel, Switzerland)
- DP303cCSPC ZhongQi Pharmaceutical Technology Co.
- DS-7300 (B7-H3 ADC)Daiichi Sankyo Company
- DS-9606aDaiichi Sankyo
- DSTA4637S (Anti-S. aureus TAC; RG7861)Genentech
- EC1169Endocyte
- EC2629Endocyte
- EDC1 (DYS-ADC)Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)
- EDC9 (EDC-CD20)Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)
- EDO-772P/B776Mundipharma EDO GmbH
- EDO-B278Mundipharma EDO GmbH
- Enapotamab vedotin | HuMax-AXL-ADC | AXL-107-MMAEGenmab in collaboration with Seattle Genetics
- Enfortumab Vedotin | Padcev | ASG-22ME | ASG-22MSEAstellas Pharma (Agensys) / Seattle Genetics
- EO-3021 also known as SYSA1801Elevation Oncology; CSPC Megalith Biopharmaceutical Co., a subsidiary of CSPC Pharmaceutical Group Limited
- EP-400Esperance Pharmaceuticals
- Epitumomab cituxetan
- Epratuzumab Tesirine | ADCT-602 | hLL2-cys-PBDADC Therapeutics
- Epratuzumab–SN-38Immunomedics
- ETx-22Emergence Therapeutics
- EV20/MMAFMediapharma
- F0002-ADC | CD30-MCC-DM1Fudan-Zhangjiang Bio-Pharmaceutica
- Farletuzumab Ecteribulin | MORAb-202Morphotek®, a subsidiary of Eisai Eisai Co Bristol Myers Squibb
- FS-1502Shanghai Fosun Pharmaceutical Development Co, Ltd.
- GC1007GeneQuantum Healthcare (Suzhou, China)
- GC1009GeneQuantum Healthcare (Suzhou, China)
- Gemtuzumab ozogamicin | Mylotarg®Pfizer (Wyeth)
- Glembatumumab vedotin | CDX-011Celldex Therapeutics, Inc.
- GM103GamaMabs
- GMF-1A3 / GMF-1A3-MMAEGundersen Medical Foundation and Kabara Cancer Research Institute
- GQ1001 - HER2GeneQuantum Healthcare (Suzhou, China)
- GQ1003 - TROP2GeneQuantum Healthcare (Suzhou, China)
- GQ1005 - HER2GeneQuantum Healthcare (Suzhou, China)
- GQ1010Pyramid Biosciences GeneQuantum Healthcare (Suzhou) Co
- GQ1014GeneQuantum Healthcare (Suzhou, China)
- GQ1015GeneQuantum Healthcare (Suzhou, China)
- GQ1017GeneQuantum Healthcare (Suzhou, China)
- GQ1018GeneQuantum Healthcare (Suzhou, China)
- Grisnilimab setaritox | WT1-RTAXenikos
- GTB-1550 | OXS-1550 | DT2219ARLGT Biopharma. Previously known as Oxis Biotech (Georgetown Translational Pharmaceuticals)
- HDP-101; Anti-CD269-ADC; Anti-CD269-amanitin-ADCHeidelberg Pharma in collaboration with Heading Medicine Co. Ltd/
- Hertuzumab VedotinRongchang Pharmaceuticals / MabPlex (Yantai, China).
- HKT288 (CDH6-ADC)Novartis and ImmunoGen
- HS-20089Hansoh BioMedical R&D Company ( Shanghai Hansoh Biomedical Co., Ltd
- HTI-1066 | SHR-A1403Jiangsu Hengrui Medicine Co.
- HTI-1511Halozyme
- HuMAB-5B1-ATACWilex/Heidelberg Pharma in collaboration with MabVax
- Ibritumomab tiuxetanBiogen Schering AG Spectrum Pharmaceuticals
- Ifinatamab Deruxtecan - DS-7300aDaiichi Sankyo, Inc. ( Daiichi Sankyo Co., Ltd.)
- IGN523Igenica Biotherapeutics
- IGN786Igenica Biotherapeutics
- IKS01Iksuda Therapeutics (formerly known as Glythera)
- IKS02Iksuda Therapeutics (formerly known as Glythera)
- IKS03Iksuda Therapeutics (formerly known as Glythera)
- IKS04Iksuda Therapeutics (formerly known as Glythera)
- Iladatuzumab vedotin | DCDS0780A | RO7032005Genentech F. Hoffmann-La Roche
- IMAB027-vcMMAEGanymed Pharmaceuticals | Astellas
- IMAB362-vcMMAEAstellas (Ganymed Pharmaceuticals)
- IMB-201ImmunoBiochem
- IMB-202ImmunoBiochem
- IMGC93650/50 co-development between MacroGenics and Immunogen
- IMGN 289ImmungoGen
- IMGN 779 | IMGN779ImmunoGen, Inc.
- IMGN-242ImmunoGen
- IMGN-388ImmunoGen
- IMGN-633 (AVE9633)ImmunoGen
- IMGN151Immunogen
- IMMU-140 (anti-HLA-DR-SN-38 ADC)Immunomedics
- Indatuximab Ravtansine | BT-062ImmunoGen | BioTest
- Indusatumab Vedotin | MLN-0264 | TAK-264Takeda / Millennium Pharmaceuticals
- Inotuzumab ozogamicin (CMC-544) | BESPONSA®Pfizer (Wyeth Pharmaceuticals)
- IPH43Innate Pharma in collaboration with AstraZeneca
- Ispectamab Debotansine - BMS-986352 - CC-99712BMS/Celgene in collaboration with Sutro
- JBH492Novartis Pharmaceuticals
- JS108Shanghai Junshi Bioscience Co., Ltd.
- KTN0125Kolltan Pharmaceuticals
- KTN0182AKolltan Pharmaceuticals
- Labetuzumab govitecan | IMMU-130Immunomedics
- Ladiratuzumab vedotin | SGN-LIV1A | Anti-LIV-1 ADCSeattle Genetics
- Laprituximab emtansine | IMGN-289 | IMGN289ImmunoGen
- LCB14-0110 (Herceptin-LC-LBG-MMAF)Legochem Biosciences and Fosun Pharma
- LCB14-15nmLegoChem Biosciences and Takeda
- LCB14-15xxLegoChem Biosciences and Y-Biologics
- LCB14-15xx (NNV019)LegoChem Biosciences and Nordic Nanovector
- LCB14-17nnLegoChem Biosciences and Gree Cross
- LCB14-19nmLegoChem Biosiences and Samsung Medical Center
- LCB14-2nmLegoChem Biosciences and Seasun Biomaterials
- Lifastuzumab Vedotin | RG-7599 | DNIB0600ARoche, F. Hoffmann-La Roche / Genentech
- Lilotomab satetraxetanNordic Nanovector ASA
- LM-302 | BMS-986476 | TPX-4589LaNova BMS (ex-China excl. Korea) Turning Point therapeutics (now part of BMS)
- LM-305LaNova AstraZeneca
- Loncastuximab tesirine | Zynlonta | ADCT-402ADC Therapeutics
- Lonigutamab Ugodotin | W0101 | W-0101Pierre Fabre In collaboration with Roche
- LOP628 (LOP-628)Novartis Pharmaceuticals
- Lorvotuzumab mertansine | IMGN-901 | LM | huN901-DM1ImmunoGen
- Losatuxizumab vedotin | ABBV-221AbbVie
- Lupartumab amadotin | BAY 1129980Bayer
- Luveltamab Tazevibulin - SΤRO-002 - LuveltaSutro Biopharma
- LY3076226Eli Lilly and Company
- M1231EMD Serono Merck KGaA, Darmstadt, Germany Sutro Biopharma
- Maridebart cafraglutide
- MDX-060 / iratumumabMedarex/Bristol-Myers Squibb
- MDX-1203 | BMS936561Medarex Bristol-Myers Squibb
- Mecbotamab Vedotin | BA3011 | CAB-Axl-ADC | CAB-anti-Axl-ADCBioAtla in collaboration with Sinobioway Biomedicine
- MEDI-547MedImmune
- MEDI3726 | ADCT-401ADC Therapeutics in collaboration with MedImmune/AstraZeneca
- MEDI4276 | MEDI 4276Medimmune / AstraZeneca
- MEN1309 | OBT076Co-developed by Menarini Ricerche and Oxford BioTherapeutics
- MGTA-117 - Amanitin ADCMagenta Therapeutics in collaboration with Heidelberg Pharma (Originator Harvard University).
- MI130004PharmaMar
- Milatuzumab doxorubicin (hLL1-DOX | IMMU-110)Immunomedics
- Mipasetamab Uzoptirine | ADCT-601ADC Therapeutics
- Mirvetuximab Soravtansine | IMGN-853 | ElahereImmunoGen (Cambridge MA USA)
- Mirzotamab Clezutoclax | ABBV-155AbbVie
- MLN-2704 | MLN2704Millennium/ Takeda
- MM-302Merrimack Pharmaceuticals, Inc.
- MRG004AShanghai Miracogen, a fully owned subsidiary of Lepu Biopharma
- MYTX-011Mythic Therapeutics
- Naratuximab emtansine | IMGN529 | K7153A | Debio 1562ImmunoGen Debiopharm Internaltional
- NBE-001NBE Therapeutics
- NBE-002 - ROR-1NBE Therapeutics GmbH
- NBE-003NBE Therapeutics
- NC-6201 (ADCM-E7974)NanoCarrier Co.,Ltd (Japan) and Eisai
- NJH395Novartis Pharmaceuticals
- NV101 (Doxorubicin-anti-CD99)NanoValent Pharmaceuticals
- NV102 (Doxorubicin-anti-CD19)NanoValent Pharmaceuticals
- NV103 (Irinotecan-anti-CD99)NanoValent Pharmaceuticals
- Oberotatug Ravtansine
- OBI-999 | Anti-Globo H ADCOBI Pharma
- OMTX503 (Anti-MTX3:Nigrin Immunoconjugate)Oncomatryx Biopharma
- OMTX705 (Anti-MTX5:Cytolysin ADC)Oncomatryx Biopharma
- Ozuriftamab Vedotin | BA3021 | Anti-ROR2 ADC | CAB-ROR2-ADCBioAtla
- Patritumab Deruxtecan | U3-1402 | HER3 ADCDaiichi Sankyo The antibody part is developed in collaboration with Amgen.
- PCA062 (PCA-062)ImmunogGen and Novartis
- Pelgifatamab Corixetan | BAY-2315497 | PSMA-TTCBayer
- PEN-221Tarveda Therapeutics
- PEN-866Tarveda Therapeutics
- Pertuzumab Zuvotolimod | SBT6050Silverback Therapeutics
- PF 06263507 (A1-mcMMAF | Anti-5T4 monoclonal antibody | PF-06263507 | PF06263507)Oxford BioMedica; Pfizer (Wyeth)
- PF-06647263 (anti-EFNA4-ADC)Pfizer
- PF-06650808 (Anti-NOTCH3 ADC)Pfizer (Wyeth)
- PF-06664178 | PF06664178 | PF 06664178Pfizer (Wyeth)
- PF-06688992 | PF06688992Memorial Sloan-Kettering Cancer Center; Pfizer
- PF-06804103 (Anti-NG-HER2 ADC)Pfizer
- Pinatuzumab vedotin | RG-7593 | DCDT2980S | DCDT-2989SGenentech / Roche, F. Hoffmann-La Roche (Roche)
- Pivekimab Sunirine | IMGN632 | IMGN 632ImmunoGen
- Polatuzumab vedotin | Polivy™ | RG-7596 | DCDS4501A | DCDS-4501AGenentech / Roche, F. Hoffmann-La Roche
- Praluzatamab Ravtansine | CX-2009CytomX Therapeutics ImmunoGen (Originator)
- PRO1160ProfoundBio
- PRO1184ProfoundBio
- Promiximab duocarmycinState Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, P.R. China
- PSMA-ADCProgenics Pharmaceuticals, Inc. (Tarrytown NY USA)
- Puxitatug samrotecan
- PYX-201Pyxis Oncology
- Q5-Drug ConjugateAlteogen
- RC108Remegen Biosciences (Shandong China), Yantai Rongchang Biological Engineering (manufactured by MabPlex)
- RC118Remegen Biosciences (Shandong China), Yantai Rongchang Biological Engineering (manufactured by MabPlex)
- RC88Remegen Biosciences (Shandong China), Yantai Rongchang Biological Engineering (manufactured by MabPlex)
- REGN2878-DM1 (Anti-PRLR-ADC)Regeneron
- REGN3124-PBDRegeneron Pharmaceuticals, Tarrytown, NY
- REGN5093 - M114Regenron
- RG-7598 (DFRF 4539A / RG7598 / RG 7598)Genentech/Roche
- RG-7841 (Anti-Ly6E / DLYE5953A)Genentech/Roche (in collaboration with Seattle Genetic)
- RG7986Genentech/Roche
- Rinatabart Sesutecan | PRO1184ProfoundBio
- RN765CPfizer/Rinat
- RN927CPfizer/Rinat
- Rolinsatamab talirine | ABBV-176AbbVie
- Rosopatamab TetraxetanWeill Cornell Medical (New York NY USA)
- Rovalpituzumab tesirine | Rova-T | SC0001 | SC16LD6.5Stemcentrx (now part of AbbVie)
- Sacituzumab govitecan | Trodelvy | IMMU-132 | hRS7-SN38Gilead Sciences (previously Immunomedics)
- Samrotamab vedotin | ABBV-085 | PR-1498487-MMAEAbbVie, Inc.
- SAR 566658 (SAR566658)Sanofi; ImmunoGen
- SAR428926ImmunoGen; Sanofi
- Satoreotide tetraxetan
- Satumomab Penditide | OncoScint® CR/OVCytogen Corporation (Primary) Chiron Theraoeutics (Europe) Knoll Pharmaceuticals (Europe) Manufacturer: Lonza Biologics
- SC-006AbbVie | Stemcentrx
- SC16LD6.5Stem CentRx
- Serclutamab Talirine | ABBV-321AbbVie
- SGN CD70 A | SGN-CD70A (superseding SGN-75)Seattle Genetics
- SGN-15 | BMS-182248 | BR96-DOXSeattle Genetics (Licensed from Bristol-Myers Squibb (BMS) with technology licensed from Enzon)
- SGN-B7H4VSeagen
- SGN-CD123A
- SGN-CD19BSeattle Genetics
- SGN-CD228ASeattle Genetics
- SGN-CD352aSeattle Genetics
- SGN-PDL1VSeagen
- SHR-A1201Jiangsu Hengrui Medicine Co. in collaboration with Beijing Shijitan Hospital
- Sirtratumab vedotin | ASG-15MEOriginated by Agensys, Ligand Pharmaceuticals and Seattle Genetics Co-developed by Astellas/Agensys and Seattle Genetics
- SKB264 ADCKLUS Pharma, a subsidiary of Kelun Pharmaceuticals (Sichuan Chengdu, China).
- SKB315Klus Pharma, the US subsidiary of China-based Kelun-Biotech.
- SNG-8023 ADCShenogen Pharma Group
- Sofituzumab vedotin | Anti-MUC16 ADC | RG7458 | DMUC5754ARoche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
- SOT102 | SO-N102SOTIO Bio
- ST1Siamab Therapeutics
- ST8176AA1Alfasigma
- STI-6129 | LNDS1001 | CD38-077Sorrento Therapeutics
- STRO-001 (Anti-CD74-ADC)Sutro Biopharma
- Sudocetaxel Zendusortide | TH1902Theratechnologies
- SYD1875 | Anti 5T4 ADC SYD1875Byondis
- Tabituximab Barzuxetan | OTSA-101-DTPAOncoTherapy Science (Japan) Centre Leon Berard
- Tacatuzumab Tetraxetan
- TAK-164Takeda (listed as Millennium Pharmaceuticals) ImmunoGen
- Tamrintamab Pamozirine | SC-003 | Anti-DPEP3 ADCAbbVie Stemcentrx LLC
- Tarcocimab Tedromer | KSI-301Kodiak Sciences
- Telisotuzumab Vedotin | ABBV 399 | ABBV-399 | Teliso-V | ABT-700-vcMMAEAbbVie
- TGM-001Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- TGM-002Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- TGM-003Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- TGM-004Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- TGM-005Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- Tisotumab Vedotin | Tivdak | HuMax®-TF-ADCCo-developed by Genmab and Seattle Genetics
- TORL-2-307-ADCTORL Biotherapeutics / Translational Research in Oncology.
- TQB2103Sino Biopharmaceutical
- TR1801-ADC | MT-8633Tanabe Research Laboratories USA in collaboration with Open Innovation Partners and MedImmune/AstraZeneca
- Trastuzumab Botidotin
- Trastuzumab Corixetan | BAY 2635190Bayer AG
- Trastuzumab deruxtecan | DS-8201, DS-8201a | ENHERTU®Daiichi Sankyo and AstraZeneca
- Trastuzumab duocarmazine | SYD985 | Trastuzumab vc-seco-DUBAByondis
- Trastuzumab Emtansine | T-DM1 | Kadcyla®Genentech Roche In collaboration with ImmunoGen
- Trastuzumab rezetecan | SHR-A1811Luzsana Biotechnology
- TRPH-222 (CD22-4AP)Triphase Accelerator Corporation, in collaboration with Catalent. The drug was originally developed by Catalent Biologics’ subsidiary Redwood Bioscience.
- Tusamitamab Ravtansine | SAR408701 | SAR 408701 | SAR-408701Sanofi | ImmunoGen
- Upifitamab Rilsodotin | XMT-1536 | UpRiMersana Therapeutics
- Vadastuximab talirine | SGN-CD33ASeattle Genetics
- Vandortuzumab vedotin (RG7450; DSTP3086S)Genentech/ F. Hoffmann-La Roche (Roche)
- VIS705Visterra
- Vobramitamab Duocarmazine | Anti-B7-H3 ADC | MGC018 | AEX4089DC1MacroGenics
- Vorsetuzumab mafodotin (SGN-75)Seattle genetics
- VYNFINIT® | Vintafolide (EC145/MK 8109)Endocyte, Merck/MSD
- XB002 ICON-2 Tissue Factor ADCExelixis / Iconic Therapeutics in collaboration with Zymeworks
- XMT-1522 | TAK-522Mersana Therapeutics in collaboration with Takeda. Antibody development: Adimab
- XMT-2056Mersana Therapeutics
- YL201MediLink Therapeutics (Suzhou) Co., Ltd.
- Zalsenertant Tetraxetan
- Zanidatamab Zovodotin | ZW49Zymeworks In collaboration with BeiGene
- ZB131 | ZB131-MMAE (ADC) | ZB131-DXd (ADC)ZielBio, Inc.
- Zilovertamab vedotin | VLS-101 | MK-2140Merck & Co (VelosBio)
- Zt/g4-DM1School of Pharmacy, Texas Tech University Health Science Center, Amarillo, TX and the Zhejiang University School of Medicine, Hangzhou, China.
- ZV05-ADC (5T4-MMAF ADC) | ZV05-mcMMAF | ZV0501Zova Biotherapeutics (Zova Bio); Concortis Biotherapeutics (a subsidiary of Sorrento Therapeutics)
- ZV203Concortis Biotherapeutics
